Keros Therapeutics, Inc. (KROS)

Over the past six months, Keros Therapeutics' stock has been impacted by several events. The company reported a net loss of $23.5 million for Q4 2025 and a net income of $87.0 million for the full year 2025, driven by revenue from a license agreement with Takeda. Keros completed a cash tender offer to repurchase approximately 10.95 million shares at $17.75 per share. The company presented additional Phase 1 clinical data for rinvatercept (KER-065) at the 2026 MDA Clinical & Scientific Conference and announced a collaboration with the Sean M. Healey & AMG Center for ALS. Charles Newton was appointed to Keros' board of directors, and Esther Cho was promoted to Chief Legal Officer. Keros' CEO presented at several healthcare conferences in late February and March 2026. KROS shares decreased by 40.7% from January 1, 2026, to May 8, 2026, trading at $12.07.

As a clinical-stage biopharmaceutical company, Keros Therapeutics, Inc. primarily focuses on the discovery and development of novel therapeutics rather than the commercial sale of established products; therefore, direct demand seasonality is not a significant factor. However, historical stock performance data suggests that KROS stock is forecast to rise based on 6 years of historical seasonality data, indicating some seasonality in its stock price movements. The company's revenue is currently growing from third-party licensing agreements rather than product sales.

Keros Therapeutics, Inc. (KROS) is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing novel therapeutics for disorders linked to dysfunctional TGF-β protein signaling. Their major product candidates include Rinvatercept (KER-065), Elritercept, and KER-012, which are in various phases of clinical trials for conditions like Duchenne Muscular Dystrophy, Amyotrophic Lateral Sclerosis, Myelodysplastic Syndromes, Myelofibrosis, pulmonary arterial hypertension and cardiovascular disorders. Keros has collaboration and license agreements with Hansoh (Shanghai) Healthtech Co., Ltd. and Takeda Pharmaceuticals U.S.A., Inc.

Keros Therapeutics, Inc. is headquartered in Lexington, Massachusetts, United States, with primary development and commercialization efforts focused there. Collaboration and license agreements for elritercept extend its reach, with Takeda Pharmaceuticals U.S.A., Inc. covering worldwide development, manufacturing, and commercialization outside of mainland China, Hong Kong, and Macau, while Hansoh (Shanghai) Healthtech Co., Ltd. covers those specific regions.

Keros Therapeutics has maintained a "Hold" consensus rating from analysts, with a MarketRank™ score indicating it performs better than 85% of evaluated companies in the medical sector. However, a previous report indicated that Keros Therapeutics' stock plummeted due to safety issues in a Phase 2 Pulmonary Arterial Hypertension (PAH) study, leading to the halting of all trial arms. Collaborations and presentations of promising clinical data for other programs can help to bolster its standing.

Keros Therapeutics, Inc. has a mixed ownership structure, with institutional shareholders holding approximately 101.81% of the stock and insiders owning about 45.83%. Major institutional owners include BlackRock, Inc., Vanguard Group Inc, and Arrowstreet Capital, Limited Partnership. Alon Lazarus is the largest individual shareholder, owning 2.04 million shares, representing 10.33% of the company.